Progesterone receptor-Grb2 interaction is associated with better outcomes in breast cancer

被引:1
作者
Wittayavimol, Nattamolphan [1 ,2 ]
Iwabuchi, Erina [3 ]
Pateetin, Prangwan [1 ,2 ]
Miki, Yasuhiro [4 ]
Onodera, Yoshiaki [3 ]
Sasano, Hironobu [3 ]
Boonyaratanakornkit, Viroj [5 ,6 ]
机构
[1] Chulalongkorn Univ, Fac Allied Hlth Sci, Dept Clin Chem, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Fac Allied Hlth Sci, Grad Program Clin Biochem & Mol Med, Bangkok 10330, Thailand
[3] Tohoku Univ, Dept Pathol, Grad Sch Med, Sendai, Japan
[4] Tohoku Univ, Int Res Inst Disaster Sci IRIDes, Dept Disaster Obstet & Gynecol, Sendai, Japan
[5] Chulalongkorn Univ, Excellence Ctr Canc & Inflammat, Bangkok, Thailand
[6] Chulalongkorn Univ, Fac Allied Hlth Sci, Dept Clin Chem, 154 Rama I Rd, Bangkok 10330, Thailand
关键词
Protein -Protein interaction; Progesterone receptor; Grb2; Breast cancer; SH3; domain; GRB2; DOWN-REGULATION; CELL LUNG-CANCER; SH3; DOMAINS; PROGNOSTIC-FACTOR; STRUCTURAL BASIS; EXPRESSION; GROWTH; OVEREXPRESSION; ESTROGEN; INHIBITION;
D O I
10.1016/j.jsbmb.2023.106441
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In addition to mediating nuclear transcription, PR mediates extranuclear functions mainly through the PR polyproline domain (PPD) interaction with the SH3 domain of cytoplasmic signaling molecules. PR-PPD-SH3 interaction inhibits EGF-mediated signaling and decreases lung cancer cell proliferation. Grb2 is an essential adaptor molecule with an SH2 domain flanked by two SH3 domains. In this study, we examined whether PR, through interaction between PR-PPD and Grb2-SH3, can interact with Grb2 in cells and breast cancer tissues. Our previous study shows that interaction between PR-PPD and Grb2 could interfere with cytoplasmic signaling and lead to inhibition of EGF-mediated signaling. GST-pulldown analysis shows that PR-PPD specifically interacts with the SH3 domains of Grb2. Immunofluorescence staining shows colocalization of PR and Grb2 in both the nucleus and cytoplasm in BT-474 breast cancer cells. Using Bimolecular Fluorescence Complementation (BiFC) analysis, we show that PR and Grb2 interact in breast cancer cells through the Grb2-SH3 domain. Proximity Ligation Assay (PLA) analysis of 43 breast cancer specimens shows that PR-Grb2 interaction is associated with low histological stage and negatively correlates with lymph node invasion and metastasis in breast cancer. These results, together with our previous findings, suggest that PR-PPD interaction with Grb2 plays an essential role in PR-mediated growth factor signaling inhibition and could contribute significantly to better prognosis in PR- and Grb2-positive breast cancer. Our finding provides a basis for additional studies to explore a novel therapeutic strategy for cancer treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
    Davey, M. G.
    Ryan, E. J.
    Folan, P. J.
    O'Halloran, N.
    Boland, M. R.
    Barry, M. K.
    Sweeney, K. J.
    Malone, C. M.
    McLaughlin, R. J.
    Kerin, M. J.
    Lowery, A. J.
    BJS OPEN, 2021, 5 (03):
  • [42] Does Androgen Receptor Have a Prognostic Role in Patients with Estrogen/Progesterone-Negative and c-erbB-2-Positive Breast Cancer?
    Arslan, Cagatay
    Isik, Metin
    Guler, Gulnur
    Kulac, Ibrahim
    Solak, Mustafa
    Turker, Burcu
    Ozisik, Yavuz
    Altundag, Kadri
    AMERICAN SURGEON, 2012, 78 (09) : 992 - 999
  • [43] Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology
    Czogalla, Bastian
    Kahaly, Maja
    Mayr, Doris
    Schmoeckel, Elisa
    Niesler, Beate
    Hester, Anna
    Zeder-Goss, Christine
    Kolben, Thomas
    Burges, Alexander
    Mahner, Sven
    Jeschke, Udo
    Trillsch, Fabian
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7673 - 7684
  • [44] Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer
    Allred, D. Craig
    MODERN PATHOLOGY, 2010, 23 : S52 - S59
  • [45] Methylated p16 gene is associated with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer
    Zhang, Shun-Li
    Wang, Ya-Qi
    Zhang, Jing-Hua
    Hu, Ji-Wei
    Ma, Jie
    Gu, Zheng
    Wang, Yu
    Chen, Jing-Jing
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (03) : 530 - 536
  • [46] Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer
    Clark, Jennifer L.
    Dresser, Karen
    Hsieh, Chung-Cheng
    Sabel, Michael
    Kleer, Celina G.
    Khan, Ashraf
    Shaw, Leslie M.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (03) : 759 - 772
  • [47] Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen
    Moon, Yong Wha
    Park, Seho
    Sohn, Joo Hyuk
    Kang, Dae Ryong
    Koo, Ja Seung
    Park, Hyung Seok
    Chung, Hyun Cheol
    Park, Byeong-Woo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (07) : 1123 - 1130
  • [48] Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer
    Eunkyung Ko
    Seong-Eun Park
    Eun Yoon Cho
    Yujin Kim
    Jung-Ah Hwang
    Yeon-Su Lee
    Seok Jin Nam
    Saik Bang
    Joobae Park
    Duk-Hwan Kim
    Breast Cancer Research, 12
  • [49] A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
    Aurilio, Gaetano
    Disalvatore, Davide
    Pruneri, Giancarlo
    Bagnardi, Vincenzo
    Viale, Giuseppe
    Curigliano, Giuseppe
    Adamoli, Laura
    Munzone, Elisabetta
    Sciandivasci, Angela
    De Vita, Fernando
    Goldhirsch, Aron
    Nole, Franco
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) : 277 - 289
  • [50] Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer
    Klijn, JGM
    Setyono-Han, B
    Foekens, JA
    STEROIDS, 2000, 65 (10-11) : 825 - 830